Last updated 2 months ago

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

360 patients around the world
Available in Spain, Brazil, Argentina, United States
GlaxoSmithKline
5Research sites
360Patients around the world
This study is for people with
Head and neck cancer
Squamous cell carcinoma of the head and neck
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Hospital Italiano de Buenos Aires - CABA, Buenos Aires
Recruiting
Juan Domingo Perón 4190, Piso 1, Ciudad Autónoma de Buenos Aires, C1181ACH
Instituto de Oncología Ángel H. Roffo - CABA, Buenos Aires
Recruiting
Av. San Martín 5481, CABA, Buenos Aires
Isis Clínica Especializada - Santa Fe
Recruiting
Urquiza 3077, Santa Fe
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
Av. Crámer 1180, CABA, Buenos Aires
Consultorios Médicos Dr. Doreski
Recruiting
Av. Cabildo, Cdad. Autónoma de Buenos Aires, Argentina
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy